“got really solid line of sight into the additional $1 billion which will be spread over 'twenty six and 'twenty seven.”

In context

“se relative to what you're able to achieve through the year in 2025? And then on Eliquis, thanks for giving the details around kind of some of those 2026 dynamics. I think you made some additional comments on that '26 to '27 transition of a $1.5 to $2 billion further step down. Can you just help us understand kind of what is driving that primary change at that moment time relative to this new baseline on pricing that we've just spoken through now. So much. Christopher Boerner: Thanks for the question, Courtney Breen. I'll ask David Elkins to take both and go from there. David Elkins: Yes. So on the cost savings program, as you saw this year, we've made really great progress against the $2 billion strategic productivity initiative. Achieving over $1 billion of that. And sitting here today, got really solid line of sight into the additional $1 billion which will be spread over 'twenty six and 'twenty seven. So you'll continue to see a step down our expense base. What I'd also say is it's also enabled us to reinvest in growth drivers, some up and we did last year with Probensi as well as Camzyos but also with a couple of the deals that we did with Orbital Therapeutics. As well as FUMITAMAG, we'll be analyzing those costs here in 'twenty six, and we're still reducing our cost basis as a result of that. Christopher Boerner: Do you want to just hit on Eliquis dynamics this year and then you and David Elkins can speak to '26 to '27? Adam Lenkowsky: Yeah. So I spoke about the Eliquis dynamics, and as Courtney Breen said, around the pricing changes that took place effective January 1, including the removal of the Medicare Part D liability and the 40% WACC reduction. So we wanted to guide against 20”